Mechanistic study of BNP7787-mediated cisplatin nephroprotection: Modulation of gamma-glutamyl transpeptidase

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 5, 2010, Pages 941-951

  Hausheer, Frederick H ^a   Shanmugarajah, Dakshine ^a   Leverett, Betsy D ^a   Chen, Xinghai ^a   Huang, Quili ^a   Kochat, Harry ^a   Petluru, Pavankumar N ^a   Parker, Aulma R ^a  

^a BioNumerik Pharmaceuticals Inc   (United States)

Author keywords

BNP7787; Cisplatin; Gamma glutamyl transpeptidase (GGT); Glutathione; Mesna disulfide heteroconjugates; Nephrotoxicity

Indexed keywords

CISPLATIN; COUMARIN DERIVATIVE; DIMESNA; GAMMA GLUTAMYLTRANSFERASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; FLUOROMETRY; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; MODULATION; NEPHROTOXICITY; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RENAL PROTECTION; SWINE; XENOBIOTIC METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; KIDNEY; MESNA; PROTECTIVE AGENTS; SWINE;

EID: 77649179448     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1101-y     Document Type: Article

References (72)

1. E Wong CM Giandomenico 1999 Current status of platinum-based antitumor drugs Chem Rev 99 2451 2466 10.1021/cr980420v 11749486
2. RS Go AA Adjei 1999 Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin J Clin Oncol 17 409 422 10458260
3. Reed E (2006) Cisplatin and analogs. In: Cancer chemotherapy and biotherapy. Chap. 14. Lippincott Williams & Wilkins, Philadelphia, pp 332-343
4. DM Townsend M Deng L Zhang MG Lapus MH Hanigan 2003 Metabolism of cisplatin to a nephrotoxin in proximal tubule cells J Am Soc Nephrol 14 1 10 10.1097/01.ASN.0000042803.28024.92 12506132 (Pubitemid 36026291)
5. J Levi C Jacobs SM Kalman M McTigue MW Weiner 1980 Mechanism of cis-platinum nephrotoxicity: I. Effects of sulfhydryl groups in rat kidneys J Pharmacol Exp Ther 213 545 550 7193725
6. H Tanaka E Ishikawa S Teshima E Shimizu 1986 Histopathological study of human cisplatin nephropathy Toxicol Pathol 14 247 257 10.1177/019262338601400215 3764321
7. I Arany RL Safirstein 2003 Cisplatin nephrotoxicity Semin Nephrol 23 460 464 10.1016/S0270-9295(03)00089-5 13680535 (Pubitemid 37176691)
8. G Daugaard U Abildgaard 1989 Cisplatin nephrotoxicity: a review Cancer Chemother Pharmacol 25 1 9 10.1007/BF00694330 2686850 (Pubitemid 20000790)
9. M Gemba N Fukuishi 1991 Amelioration by ascorbic acid of cisplatin-induced injury in cultured renal epithelial cells Contrib Nephrol 95 138 142 1807906
10. NE Madias JT Harrington 1978 Platinum nephrotoxicity Am J Med 65 307 314 10.1016/0002-9343(78)90825-2 99034 (Pubitemid 9003377)
11. S Meijer DT Sleijfer NH Mulder WJ Sluiter J Marrink HS Koops TM Brouwers J Oldhoff GK van der Hem E Mandema 1983 Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma Cancer 51 2035 2040 10.1002/1097-0142(19830601)51:11<2035::AID- CNCR2820511113>3.0.CO;2-8 6340821
12. JJ Offerman S Meijer DT Sleijfer NH Mulder AJ Donker HS Koops GK van der Hem 1984 Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function Cancer Chemother Pharmacol 12 36 38 10.1007/BF00255906 6537801
13. MW Weiner C Jacobs 1983 Mechanism of cisplatin nephrotoxicity Fed Proc 42 2974 2978 6684595
14. DC Dobyan J Levi C Jacobs J Kosek MW Weiner 1980 Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations J Pharmacol Exp Ther 213 551 556 7193726
15. JC Gonzales-Vitale DM Hayes E Cvitkovic SS Sternberg 1977 The renal pathology in clinical trials of cis-platinum (II) diamminedichloride Cancer 39 1362 1371 10.1002/1097-0142(197704)39:4<1362::AID-CNCR2820390403>3.0.CO;2- N 851939
16. MK Kuhlmann G Burkhardt H Kohler 1997 Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application Nephrol Dial Transplant 12 2478 2480 10.1093/ndt/12.12.2478 9430835
17. MH Hanigan BC Gallagher PT Taylor Jr MK Large 1994 Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity Cancer Res 54 5925 5929 7954424
18. MH Hanigan BC Gallagher PT Taylor Jr 1996 Cisplatin nephrotoxicity: inhibition of gamma-glutamyl transpeptidase blocks the nephrotoxicity of cisplatin without reducing platinum concentrations in the kidney Am J Obstet Gynecol 175 270 274 10.1016/S0002-9378(96)70134-5 8765241
19. L Zhang MH Hanigan 2003 Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin J Pharmacol Exp Ther 306 988 994 10.1124/jpet.103.052225 12750429 (Pubitemid 37025305)
20. MH Hanigan ED Lykissa DM Townsend CN Ou R Barrios MW Lieberman 2001 Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin Am J Pathol 159 1889 1894 11696449
21. DM Townsend MH Hanigan 2002 Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice J Pharmacol Exp Ther 300 142 148 10.1124/jpet.300.1.142 11752109 (Pubitemid 34028520)
22. AK Godwin A Meister PJ O'Dwyer CS Huang TC Hamilton ME Anderson 1992 High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis Proc Natl Acad Sci USA 89 3070 3074 10.1073/pnas.89.7.3070 1348364
23. MH Hanigan BC Gallagher DM Townsend V Gabarra 1999 Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo Carcinogenesis 20 553 559 10.1093/carcin/20.4.553 10223181
24. M Benlloch A Ortega P Ferrer R Segarra E Obrador M Asensi J Carretero JM Estrela 2005 Acceleration of glutathione efflux and inhibition of gamma-glutamyl transpeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity J Biol Chem 280 6950 6959 10.1074/jbc.M408531200 15561710 (Pubitemid 40341251)
25. E Ruttmann LJ Brant H Concin G Diem K Rapp H Ulmer 2005 Gamma-glutamyl transferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163, 944 Austrian adults Circulation 112 2130 2137 10.1161/CIRCULATIONAHA.105.552547 16186419 (Pubitemid 41475806)
26. A Paolicchi G Minotti P Tonarelli R Tongiani CD De A Mezzetti S Dominici M Comporti A Pompella 1999 Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation: a potential mechanism in atherosclerosis J Investig Med 47 151 160 10198571
27. MH Hanigan 1998 Gamma-glutamyl transpeptidase, a glutathionase: its expression and function in carcinogenesis Chem Biol Interact 111-112 333 342 10.1016/S0009-2797(97)00170-1 9679564 (Pubitemid 28271953)
28. MH Hanigan HC Pitot 1985 Gamma-glutamyl transpeptidase: its role in hepatocarcinogenesis Carcinogenesis 6 165 172 10.1093/carcin/6.2.165 2857599
29. SS Tate A Meister 1981 Gamma-glutamyl transpeptidase: catalytic, structural and functional aspects Mol Cell Biochem 39 357 368 10.1007/BF00232585 6118826
30. JW Keillor R Castonguay C Lherbet 2005 Gamma-glutamyl transpeptidase substrate specificity and catalytic mechanism Methods Enzymol 401 449 467 10.1016/S0076-6879(05)01027-X 16399402 (Pubitemid 43052408)
31. SM Deneke BL Fanburg 1989 Regulation of cellular glutathione Am J Physiol 257 L163 L173 2572174
32. E Boven M Verschraagen TM Hulscher CA Erkelens FH Hausheer HM Pinedo WJF van der Vijgh 2002 BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts Eur J Cancer 38 1148 1156 10.1016/S0959-8049(02)00036-9 12008205 (Pubitemid 34468022)
33. FH Hausheer P Kanter S Cao K Haridas P Seetharamulu D Reddy P Petluru M Zhao D Murali JD Saxe S Yao N Martinez A Zukowski YM Rustum 1998 Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents Semin Oncol 25 584 599 9783598
34. L Pendyala G Schwartz P Smith J Zdanowicz M Murphy F Hausheer 2003 Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy Cancer Chemother Pharmacol 51 376 384 12682786
35. FH Hausheer H Kochat AR Parker D Ding S Yao SE Hamilton PN Petluru BD Leverett SH Bain JD Saxe 2003 New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent Cancer Chemother Pharmacol 52 Suppl 1 S3 S15 10.1007/s00280-003-0653-5 12819940
36. M Verschraagen E Boven R Ruijter K van der Born J Berkhof FH Hausheer WJF van der Vijgh 2003 Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites Clin Pharmacol Ther 74 157 169 10.1016/S0009-9236(03)00150-4 12891226 (Pubitemid 36951813)
37. E Boven M Westerman CJ van Groeningen M Verschraagen R Ruijter I Zegers WJF van der Vijgh G Giaccone 2005 Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule Br J Cancer 92 1636 1643 10.1038/sj.bjc.6602553 15841080 (Pubitemid 40756473)
38. Hausheer F, Kanter P, Rustum Y, Cao S, Haridas K, Reddy D, Seetharamulu P, Zhao M, Yao S, Pavankumar P, Murali D (1997) Abstract #2089: BNP7787: A novel antitumor potentiating drug which protects against cisplatin and carboplatin toxicities. In: Proceedings of the AACR (88th annual meeting), vol 38, p 311
39. Hausheer F, Cavaletti G, Tredici G, Oggioni N, Spinelli S, Pezzoni G, Manzotti C, Haridas K, Reddy D, Zhao M, Seetharamulu P, Yao S, Pavankumar P, Murali D, Wu M, Saxe J, Cavalletti E (1999) Abstract #2633: Oral and intravenous BNP7787 protects against platinum neurotoxicity without in vitro or in vivo tumor protection. In: Proceedings of the AACR (90th annual meeting), vol 40, p 398
40. Hausheer FH, Rustum Y, Cao S, Haridas K, Reddy D, Seetharamalu P, Zhao M, Yao S, Pavankumar P, Murali D (1998) Abstract #1077: BNP7787-Administration in vivo results in increased therapeutic index and toxicity reduction of platinum drugs. In: Proceedings of the AACR (89th annual meeting), vol 39, p 158
41. D Shanmugarajah D Ding Q Huang X Chen H Kochat PN Petluru PY Ayala AR Parker FH Hausheer 2009 Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high-performance liquid chromatography J Chromatogr B Analyt Technol Biomed Life Sci 877 857 866 10.1016/j.jchromb.2009.02.056 19278906
42. Shanmugarajah D (2007) Mechanism of action of BNP7787, a novel chemoprotective agent. Dissertation, presented to the University of Texas Health Science Center at San Antonio
43. K Ormstad N Uehara 1982 Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat FEBS Lett 150 354 358 10.1016/0014-5793(82)80767-9 6819161 (Pubitemid 13184074)
44. M Verschraagen E Boven E Torun CA Erkelens FH Hausheer WJF van der Vijgh 2004 Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats Br J Cancer 90 1654 1659 10.1038/sj.bjc.6601719 15083199 (Pubitemid 38648252)
45. SS Tate A Meister 1974 Interaction of gamma-glutamyl transpeptidase with amino acids, dipeptides, and derivatives and analogs of glutathione J Biol Chem 249 7593 7602 4154944
46. GA Thompson A Meister 1977 Interrelationships between the binding sites for amino acids, dipeptides, and gamma-glutamyl donors in gamma-glutamyl transpeptidase J Biol Chem 252 6792 6798 19479
47. GA Thompson A Meister 1975 Utilization of l-cystine by the gamma-glutamyl transpeptidase-gamma-glutamyl cyclotransferase pathway Proc Natl Acad Sci USA 72 1985 1988 10.1073/pnas.72.6.1985 237267
48. HJ Forman MM Shi T Iwamoto RM Liu TW Robison 1995 Measurement of gamma-glutamyl transpeptidase and gamma-glutamylcysteine synthetase activities in cells Methods Enzymol 252 66 71 10.1016/0076-6879(95)52009-0 7476375
49. GD Smith JL Ding TJ Peters 1979 A sensitive fluorimetric assay for gamma-glutamyl transferase Anal Biochem 100 136 139 10.1016/0003-2697(79)90122-2 44433 (Pubitemid 10157642)
50. PE Kintzel 2001 Anticancer drug-induced kidney disorders Drug Saf 24 19 38 10.2165/00002018-200124010-00003 11219485
51. MM Jones MA Basinger MA Holscher 1992 Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds Fundam Appl Toxicol 18 181 188 10.1016/0272-0590(92)90044-I 1601218
52. DS Alberts WA Bleyer 1996 Future development of amifostine in cancer treatment Semin Oncol 23 90 99 8783674
53. DR Gandara VJ Wiebe EA Perez RW Makuch MW DeGregorio 1990 Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate Crit Rev Oncol Hematol 10 353 365 10.1016/1040-8428(90) 90010-P 2177606
54. G Kemp P Rose J Lurain M Berman A Manetta B Roullet H Homesley D Belpomme J Glick 1996 Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer J Clin Oncol 14 2101 2112 8683243
55. M Verschraagen TH Zwiers PE de Koning J Welink WJF van der Vijgh 2001 Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection J Chromatogr B Biomed Sci Appl 753 293 302 10.1016/S0378-4347(00)00563-6 11334343 (Pubitemid 32217729)
56. M Verschraagen K van der Born TH Zwiers WJF van der Vijgh 2002 Simultaneous determination of intact cisplatin and its metabolite monohydrated cisplatin in human plasma J Chromatogr B Analyt Technol Biomed Life Sci 772 273 281 10.1016/S1570-0232(02)00108-3 12007772 (Pubitemid 34499574)
57. M Verschraagen TH Zwiers E Torun MG Donker NJ Reinhoud WJF van der Vijgh 2003 Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector J Pharm Sci 92 1040 1050 10.1002/jps.10363 12712424 (Pubitemid 36523450)
58. M Verschraagen M Bosma TH Zwiers E Torun WJF van der Vijgh 2003 Quantification of mesna and total mesna in kidney tissue by high-performance liquid chromatography with electrochemical detection J Chromatogr B Analyt Technol Biomed Life Sci 783 33 42 10.1016/S1570-0232(02)00470-1 12450522 (Pubitemid 35351630)
59. M Verschraagen MA Kedde FH Hausheer WJF van der Vijgh 2003 The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG Cancer Chemother Pharmacol 51 499 504 12715205
60. M Verschraagen E Boven E Torun FH Hausheer A Bast WJF van der Vijgh 2004 Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects Biochem Pharmacol 68 493 502 10.1016/j.bcp.2004.04.005 15242815 (Pubitemid 38887431)
61. Hausheer FH, Kochat H, Reddy D, Zhao M, Seetharamulu P, Yao S, Pavankumar P, Murali D, Wu M, Saxe J, Parker A, Hamilton S (2000) Abstract #4890: BNP7787: A novel chemoprotecting agent for platinum and taxane toxicity. In: Proceedings of the AACR (91st annual meeting), vol 41, pp 769-770
62. Hausheer FH, Kochat H, Zhao M, Hamilton S, Wu M, Seetharamulu P, Petluru P, Huang Q, Chen X, Ma H, Ding D, Leverett B, Wu Y, Wang J, Saxe J, Parker A, Berghorn E (2001) Abstract #1990: BNP7787, A novel neuroprotective agent in taxane and platinum regimens, does not interfere with antitumor activity. In: Proceedings of the AACR (92nd annual meeting), vol 42, p 370
63. MW Anders W Dekant 1998 Glutathione-dependent bioactivation of haloalkenes Annu Rev Pharmacol Toxicol 38 501 537 10.1146/annurev.pharmtox.38.1. 501 9597164
64. W Dekant 1993 Bioactivation of nephrotoxins and renal carcinogens by glutathione S-conjugate formation Toxicol Lett 67 151 160 10.1016/0378-4274(93) 90052-Y 8451756 (Pubitemid 223051330)
65. W Dekant S Vamvakas MW Anders 1994 Formation and fate of nephrotoxic and cytotoxic glutathione S-conjugates: cysteine conjugate beta-lyase pathway Adv Pharmacol 27 115 162 10.1016/S1054-3589(08)61031-5 8068551
66. W Dekant D Henschler 1999 Organ-specific carcinogenicity of haloalkenes mediated by glutathione conjugation J Cancer Res Clin Oncol 125 174 181 10.1007/s004320050260 10235471 (Pubitemid 29172508)
67. W Dekant 2001 Chemical-induced nephrotoxicity mediated by glutathione S-conjugate formation Toxicol Lett 124 21 36 10.1016/S0378-4274(00)00285-X 11684355 (Pubitemid 33000346)
68. T Okada H Suzuki K Wada H Kumagai K Fukuyama 2007 Crystal structure of the gamma-glutamyl transpeptidase precursor protein from Escherichia coli: structural changes upon autocatalytic processing and implications for the maturation mechanism J Biol Chem 282 2433 2439 10.1074/jbc.M607490200 17135273 (Pubitemid 47076749)
69. T Okada H Suzuki K Wada H Kumagai K Fukuyama 2006 Crystal structures of gamma-glutamyl transpeptidase from Escherichia coli, a key enzyme in glutathione metabolism, and its reaction intermediate Proc Natl Acad Sci USA 103 6471 6476 10.1073/pnas.0511020103 16618936
70. A Andersson A Isaksson L Brattstrom B Hultberg 1993 Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatization Clin Chem 39 1590 1597 8353942
71. WA Kleinman JP Richie Jr 2000 Status of glutathione and other thiols and disulfides in human plasma Biochem Pharmacol 60 19 29 10.1016/S0006-2952(00) 00293-8 10807941 (Pubitemid 30243081)
72. IC Shaw MI Graham 1987 Mesna: a short review Cancer Treat Rev 14 67 86 10.1016/0305-7372(87)90041-7 3119211 (Pubitemid 18000585)